Why the study?
How do advanced heart failure, liver disease, and renal failure affect the pharmacokinetics of intravenous lidocaine compared to normal subjects?
Population
35 subjects including 10 normal subjects, 11 patients with heart failure, 8 patients with alcoholic liver…
Comparison
Intravenously administered lidocaine vs Normal subjects
Design
Cohort
Authors
Loading...
May support reduced lidocaine dosing in heart failure or liver disease; extends pharmacokinetic data but leaves open prospective validation.
How do advanced heart failure, liver disease, and renal failure affect the pharmacokinetics of intravenous lidocaine compared to normal subjects?
Lidocaine dosage regimens or infusion rates should be decreased in patients with advanced heart failure or liver disease due to significantly reduced plasma clearance.
Pate D. Thomson (1973) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: